Pediatric Voniconazole

 

This reference library was created for the community of providers who care for children with these illnesses. It was developed to assist clinicians in understanding, diagnosing and treating pediatric invasive fungal infections. The library links to important references within each category but is not meant to be comprehensive. 

 

Return to Library Home

 

 

 

 

 

 

 

 

 

 

International Pediatric Fungal Network, Box 3499, Duke University Medical Center, Durham, NC 27710. USA.   Tel: 919-668-4847 Email: PFNContracts@duke.edu

Voriconazole prophylaxis in children with cancer: changing outcomes and epidemiology of fungal infections. 

Maron GM et al. Pediatr Infect Dis J. 2013 Dec;32(12):e451-5.

Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. 

Friberg LE et al. Antimicrob Agents Chemother. 2012 Jun;56(6):3032-42.

Impact of therapeutic drug monitoring of voriconazole in a pediatric population. 

Bruggemann RJ et al. Pediatr Infect Dis J. 2011 Jun;30(6):533-4.


Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. 

Karlsson MO et al. Antimicrob Agents Chemother. 2009 Mar;53(3):935-44.

Oral voriconazole dose in children: one size does not fit all. 

Goutelle S et al. Clin Infect Dis. 2010 Oct 1;51(7):870; author reply 871. doi: 10.1086/656293.

Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis. 

Choi SH et al. Pediatr Blood Cancer. 2013 Jan;60(1):82-7.

Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events. 

Chu HY et al. BMC Infect Dis. 2013 Feb 26;13(1):105. 

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. 

Driscoll TA et al. Antimicrob Agents Chemother. 2011 Dec;55(12):5770-9.

Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients. 

Michael C et al. Antimicrob Agents Chemother. 2010 Aug;54(8):3225-32.

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

Walsh TJ et al. Antimicrob Agents Chemother. 2010 Oct;54(10):4116-23.

Highly variable plasma concentrations of voriconazole in pediatric hemoatopoietic stem cell transplantation patients. 

Bartelink IH et al. Antimicrob Agents Chemother. 2013 Jan;57(1):235-40.